





BUENOS AIRES, VOL. 83 Supl. V - 2023

COMITÉ DE REDACCIÓN

Sebastián F. Ameriso

FLENI, Buenos Aires, Argentina

Pablo J. Azurmendi

Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

Damasia Becú Villalobos

Instituto de Biología y Medicina Experimental-CONICET,

Buenos Aires, Argentina

Gabriela V. Carro

Hospital Nacional Prof. A. Posadas

Buenos Aires, Argentina

José H. Casabé

Instituto de Cardiología y Cirugía Cardiovascular, Hospital Universitario Fundación Favaloro, Buenos Aires, Argentina

Hugo N. Catalano

Hospital Alemán, Buenos Aires, Argentina

Eduardo L. De Vito

Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina Elisa Estenssoro

Hospital Interzonal de Agudos General San Martín de La Plata,

Buenos Aires, Argentina Laura I. Jufe

Hospital General de Agudos J. M. Ramos Mejía,

Isabel Narvaiz Kantor

Organización Panamericana de la Salud (OPS/OMS), Argentina

Basilio A. Kotsias

Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

Gustavo Kusminsky

Hospital Universitario Austral, Buenos Aires, Argentina

Oscar M. O. Laudanno

Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina Isabel A. Lüthy

Instituto de Biología y Medicina Experimental (IBYME),

Buenos Aires, Argentina

Domingo J. Palmero Hospital de Infecciosas Dr. Francisco J. Muñiz

Instituto de Tisioneumonología Prof. Dr. Raúl Vacarezza,

Facultad de Medicina, UBA, Argentina Guillermo B. Semeniuk

Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

Osvaldo J. Stringa

Hospital de Clínicas José de San Martín, UBA, Argentina

Carlos D. Tajer

Hospital de Alta Complejidad El Cruce Néstor Kirchner, Buenos Aires, Argentina

MIEMBROS EMÉRITOS

Héctor O. Alonso

Instituto Cardiovascular Rosario, Santa Fe, Argentina

María Marta de Elizalde de Bracco

IMEX-CONICET-Academia Nacional de Medicina, Buenos Aires, Argentina

Guillermo Jaim Etcheverry

Facultad de Medicina, UBA, Argentina

Daniel A. Manigot

Hospital San Juan de Dios, Buenos Aires, Argentina

Rodolfo S. Martin

Facultad de Ciencias Biomédicas,

Hospital Universitario Austral, Buenos Aires, Argentina

La Tapa Todo, 2016

Daniela Kantor

MEDICINA (Buenos Aires) - Revista bimestral – ISSN 1669-9106 (En línea)

Registro de la Propiedad Intelectual Nº 02683675

Personería Jurídica N° C-7497

Publicación de la Fundación Revista Medicina (Buenos Aires) Propietario de la publicación: Fundación Revista Medicina Queda hecho el depósito que establece la Ley 11723

Publicada con el apoyo del Ministerio de Ciencia, Tecnología e Innovación Productiva.

MEDICINA no tiene propósitos comerciales. El objeto de su creación ha sido propender al adelanto de la medicina argentina.

Los beneficios que pudieran obtenerse serán aplicados exclusivamente a este fin.

Aparece en MEDLINE (PubMed), ISI-THOMSON REUTERS (Journal Citation Report, Current Contents, Biological Abstracts, Biosis, Life Sciences), CABI (Global Health), ELSEVIER (Scopus, Embase, Excerpta Medica), SciELO, LATINDEX, BVS

(Biblioteca Virtual en Salud), DOAJ, Google Scholar y Google Books.
Incluida en el Núcleo Básico de Revistas Científicas Argentinas del CONICET.

Directores Responsables:

Eduardo L. De Vito, Isabel Lüthy, Oscar M. O. Laudanno, Isabel Narvaiz Kantor

Secretaría de Redacción: Ethel Di Vita, Instituto de Investigaciones Médicas Alfredo Lanari, Combatientes de Malvinas 3150, 1427 Buenos Aires, Argentina

e-mail: revmedbuenosaires@gmail.com – http://: www.medicinabuenosaires.com

Vol. 83, Supl. V, Noviembre 2023

Diagramación y Diseño: Andrés Esteban Zapata - aez.sgi@gmail.com

REUNIÓN CONJUNTA SAIC SAB AAFE AACYTAL 2023

LXVIII REUNIÓN ANUAL DE LA SOCIEDAD ARGENTINA DE INVESTIGACIÓN CLÍNICA (SAIC)

XXV JORNADAS ANUALES DE LA SOCIEDAD ARGENTINA DE BIOLOGÍA (SAB)

LV REUNIÓN ANUAL DE LA ASOCIACIÓN ARGENTINA DE FARMACOLOGÍA EXPERIMENTAL (AAFE)

VIII REUNIÓN CIENTÍFICA REGIONAL DE LA ASOCIACIÓN ARGENTINA DE CIENCIA Y TECNOLOGÍA DE ANIMALES DE LABORATORIO (AACYTAL)

> 15-17 de noviembre de 2023 Hotel 13 de Julio – Mar del Plata

EDITORES RESPONSABLES
Dra. Isabel Luthy
Dra. Silvina Pérez Martínez
Dr. Ventura Simonovich
Dr. Gabriel Pinto

JOINT MEETING SAIC SAB AAFE AACYTAL 2023

LXVIII ANNUAL MEETING OF SOCIEDAD ARGENTINA DE INVESTIGACIÓN CLÍNICA (SAIC)

XXV ANNUAL CONFERENCES OF SOCIEDAD ARGENTINA DE BIOLOGÍA (SAB)

LV ANNUAL MEETING OF ASOCIACIÓN ARGENTINA DE FARMACOLOGÍA EXPERIMENTAL (AAFE)

VIII REGIONAL SCIENTIFIC MEETING OF ASOCIACIÓN ARGENTINA DE CIENCIA Y TECNOLOGÍA DE ANIMALES DE LABORATORIO (AACYTAL)

> November 15-17, 2023 13 de Julio Hotel – Mar del Plata

> > RESPONSIBLE EDITORS
> > Dra. Isabel Luthy
> > Dra. Silvina Pérez Martínez
> > Dr. Ventura Simonovich
> > Dr. Gabriel Pinto

ABSTRACTS 103

tissue involved.

92. 86. EFFECT OF ESTROGEN ESTRONE ON UTERINE AND ADIPOSE TISSUE UNDER OBESITY

María I. Valle, Sabrina B. Cepeda, Pablo H. Cutini, Marisa J. Sandoval, Virginia L. Massheimer

Instituto de Ciencias Biológicas y Biomédicas del Sur (INBIO-SUR), CONICET-Universidad Nacional del Sur (UNS). Departamento de Biología, Bioquímica y Farmacia. UNS. Bahía Blanca. Argentina

Previously we reported that, estrone (E₄) counteracts uterine oxidative stress induced by an inflammatory environment. In this work, using an experimental model of obesity, the direct action of E, on uterus (Ut) and adipose tissue (AT) was evaluated. In order to rule out the influence of the hormonal impact during estrous cycle, animals were bilaterally ovariectomized (OVX). Rats were fed with high-fat diet (OVX-Ob) for 10 weeks. After isolation, Ut and retroperitoneal AT explants were in vitro expose to 10 nM E. Histological analysis of Ut explants (H&E staining) showed that in non-OVX rats exhibited a thicker endometrial layer with great amount of uterine glands compared to uterus sections from OVX rats, verifying the absence of estrous cycles in OVX group. The serum biochemical evaluation showed that, Ob rats exhibited higher levels of serum H2O2; TBARS, and leptin than non-obese (8; 65; 122% above non-Ob, respectively, p< 0.05), profile compatible with obesity. After E1 treatment (4h), Ut slices exhibited an enhancement in nitric oxide synthesis (33% above control P<0.001) and reduction in ROS production (30% below control, P<0.01). To assess whether the effect of E, on H₂O₂ generation depends on its ability to enhance NO synthesis, an irreversible NOS inhibitor (L-NAME) was employed. In the presence of L-NAME, the reduction on ROS production elicited by E1 was blocked, suggesting NO dependence. Indeed, in OVX-Ob rats the steroid treatment stimulates uterus angiogenesis. Concomitantly, on AT explants isolated from OVX-Ob rats, E, prompted an antioxidant action. E, reduced H₂O₂ secretion (2375±263 vs 1978±241 nmol/g AT, C vs E1 p<0.05), and TBARS released (502±195 vs 353±30 nmol/g AT, C vs E, p<0.05). Indeed, a 14% reduction on leptin secretion was also detected (p<0.05). The results presented evidenced that adipose tissue is targeted of E, action, and that under obesity the hormone exerts a protective action on Ut and AT reducing oxidative stress

93. 168. OVARIECTOMY PREVENTS THE LOSS OF NUCLE-AR MENIN EXPRESSION IN LACTOTROPHS PREVENT-ING PROLACTINOMA DEVELOPMENT

Milagros Peña-Zanoni, Alejandra Abeledo-Machado, Dana Bornancini, Agustina Marcial-López, Susana Rulli, Graciela Díaz-Torga.

Instituto de Biología y Medicina Experimental, Buenos Aires.

Among its multiple functions, menin plays a key role in activins signalling in the pituitary. We previously showed the importance of activin inhibitory function on lactotrophs: decreased activin biological function is involved in prolactinoma development. Moreover, the loss of gonadal inhibins after a prepuberal ovariectomy (OVX) recovers the inhibitory function of pituitary activins preventing prolactinoma development. In this work, we analysed the effect induced by a prepuberal OVX on menin expression and cellular localization in lactotrophs, and its impact on menin targets as: Inhbb gene (which encodes activin subunit βb), p27^{Kip1} and pAKT. We used a mouse model of prolactinoma: females overexpressing the β subunit of the human chorionic gonadotrophin (hCGβ+). Data was analysed by One-way ANOVA comparing groups: WT (normal pituitaries) vs hCGβ+ (prolactinomas) vs hCGβ+OVX (hCGβ+ with prepuberal OVX). We found nuclear and cytoplasmatic menin expression in lactotrophs from WT female mice (confocal microscopy). The nuclear expression of menin was lost in prolactinomas (hCGβ+ females). Accordingly, hCGB+ prolactinomas presented lower levels of Inhbb (RTqPCR), reduced p27 expression in lactotrophs, with a concomitant sharp increase in the percentage of lactotrophs pAKT+ compared to WTs. Interestingly, after OVX, the nuclear localization of menin is recovered (hCGβ+OVX group). Accordingly, pituitary Inhbb levels sharply increases, the percentage of lactotrophs p27+ was recovered, with concomitant reduction in the percentage of lactotroph pAKT+ in hCG β +OVX pituitaries. The present results demonstrate that a prepuberal OVX not only recovers activin inhibitory action but also prevents the loss of nuclear menin expression in lactotrophs, avoiding p27 dysregulation and pAKT increase, preventing prolactinoma development.

94. 197. DEXAMETHASONE ACCELERATES WHITENING AF-TER BROWNING OF WHITE ADIPOSE TISSUE IN MICE

Alejandra Giordano¹, Patricia Castro¹, María Amanda Rey¹, María Guillermina Zubiría¹, Andrés Giovambattista¹

¹Instituto Multidisciplinario de Biología Celular (IMBICE) CONICET-CICPBA-UNLP

Browning is the emergence of thermogenic beige adipocytes in white adipose tissue (WAT), mainly in response to cold or B-adrenergic stimuli. Previously, we demonstrated that Dexamethasone (Dxm) inhibits browning in WAT depots from rats. However, it remains unexplored the Dxm effect in beige to white adipocyte transition (Whitening, wtng) and its relationship with mitophagy activation. Our aim was to study if Dxm affect this process in mouse inguinal AT (IAT), using in vivo and in vitro models. First, male mice were kept at 4°C during 7 days (CF) and then two groups were housed during 8h or 2 days at RT and treated daily with or without Dxm (Sc. injection: 0.03 mg/kg; experimental groups: DW8h, CW8h, DW2d and CW2d, respectively). IAT pads were dissected and processed for quantification (qPCR) of thermogenic (Ucp1) and mitophagy (Pink1 and Parkn2) marker expressions. We evaluated the effect of the variables Time (T) and Dxm (2-way ANOVA). First, we found that Dxm diminished Ucp-1 mRNA levels (p<0.05) at both times, supporting a stimulatory effect of Dxm in IAT wtng. On the other hand, Dxm caused differential effect in Pink1 and Parkn2 expressions: at 8h both markers were increased while at 2 days both were similar to control (Interaction TxDxm p<0.05), indicating an accelerate activation of mitophagy by Dxm. We also evaluated the in vitro Dxm effect in wtng process, using differentiated beige adipocytes. During the last 12h or 24h of culture T3 and rosiglitazone were withdrawn to allow wtng process occurs, and cells were incubated with or without Dxm 0,25 uM. We found that Dxm decreased Ucp1 and increased pink1 mRNA levels, in both times (p<0.05). While, Prkn2 and Resistin (white adipocyte marker) expressions were increased only at 24h, indicating a higher effect of Dxm at longer times (Interaction TxDxm p<0.05). Overall, here we described for the first time that Dxm accelerates the wtng of IAT, which could be due to an increase in mitophagy-related genes expression

95. 241. SPEXIN PROMOTES WHITENING OF WHITE ADI-POSE TISSUE THROUGH MODULATION OF AUTOPHA-GY

Patricia Castro¹, Catalina Latina¹, Agustina Castro¹, Sabrina Gambaro^{1,2}, Andrés Giovambattista^{1,2}

¹ Instituto Multidisciplinario de Biología Celular (IMBICE) CO-NICET-CICPBA-UNLP

²Facultad de Ciencias Exactas, UNLP

Spexin (SPX), a peptide adipokine, has been involved in many metabolic processes such as body weight regulation, food intake, energy balance and glucose and lipid metabolism. Recently, it was also related to disrupt the thermogenic profile of brown and white adipose tissue (AT), but no information was found about its role during white adipose tissue whitening. For this purpose, C57BL/6J male mice were exposed 7 days at 4°C and then returned to room temperature for 8h or 24h where spx was administered (ip. 29 μ g/kg; 8SPXw and 24SPXw) or PBS (8CTRw and 24CTRw). Body weight and caloric intake were recorded daily. At the end of the experiment, plasma was collected for Triglycerides (TG) measurement and Epididymal AT (EAT) and Inguinal AT (IAT) was dissected and weighted. IAT was also processed for qPCR gene expression (Ucp1; thermogenic marker and Pink, Parkin, Atg12 and Atg7; autophagic markers) and for mitochondrial DNA (mitDNA) quantification. Two-way ANO-VA was used to determine variable (SPX and Time) and interaction (SPX x Time) effects. No differences in total caloric intake were ob-